Patents by Inventor Stephan Schilling
Stephan Schilling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11703511Abstract: The present invention can be included in the field of medicine. Specifically, the present invention provides antibodies and antigen-binding fragments thereof which can bind isoAsp7 amyloid ? (A?) and a pharmaceutical composition comprising the antibodies or antigen-binding fragments thereof. IsoAsp7 A? can be found in plaques of Alzheimer's patients and is thus a suitable target for the treatment and/or prevention of A?-related diseases such as Alzheimer's disease. Thus, the antibodies, antigen-binding fragments thereof and the pharmaceutical composition comprising either can be used to treat and/or prevent neurodegenerative diseases. Further, the present invention provides hybridoma cell lines, the use of the antibodies or antigen-binding fragments thereof for the diagnosis and/or prognosis of a neurodegenerative disease and a method for detecting isoAsp7 A? in an isolated sample.Type: GrantFiled: July 17, 2018Date of Patent: July 18, 2023Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.Inventors: Anke Piechotta, Kathrin Gnoth, Holger Cynis, Jens-Ulrich Rahfeld, Stephan Schilling, Hans-Ulrich Demuth
-
Publication number: 20230122243Abstract: The present invention relates to novel hydroxamic acid derivatives useful as inhibitors of astacin metalloproteinases, in particular procollagen C-proteinase (PCP) enzymes, meprins, ovastacin and/or nematode astacins; more particularly human or mammalian meprin ?, meprin ?, BMP-1, ovastacin and/or DPY-31 from nematodes; pharmaceutical compositions comprising such compounds; methods for treatment or prophylaxis of diseases or conditions, especially such that are related to said metalloproteinases; and compounds and pharmaceutical compositions for use in such methods.Type: ApplicationFiled: June 12, 2020Publication date: April 20, 2023Inventors: Daniel RAMSBECK, Kathrin TAN, Dagmar SCHLENZIG, Mirko BUCHHOLZ, Holger CYNIS, Stephan SCHILLING
-
Patent number: 11045533Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.Type: GrantFiled: January 16, 2020Date of Patent: June 29, 2021Inventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies
-
Publication number: 20210032315Abstract: The invention relates to humanized and de-immunized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of monoclonal antibodies of the invention to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the antibodies of the invention.Type: ApplicationFiled: January 29, 2019Publication date: February 4, 2021Inventors: Jens-Ulrich RAHFELD, Stephen Gillies, Thore HETTMANN, Stephan SCHILLING, Martin KLEINSCHMIDT
-
Publication number: 20200264197Abstract: The present invention can be included in the field of medicine. Specifically, the present invention provides antibodies and antigen-binding fragments thereof which can bind isoAsp7 amyloid ? (A?) and a pharmaceutical composition comprising the antibodies or antigen-binding fragments thereof. IsoAsp7 A? can be found in plaques of Alzheimer's patients and is thus a suitable target for the treatment and/or prevention of A?-related diseases such as Alzheimer's disease. Thus, the antibodies, antigen-binding fragments thereof and the pharmaceutical composition comprising either can be used to treat and/or prevent neurodegenerative diseases. Further, the present invention provides hybridoma cell lines, the use of the antibodies or antigen-binding fragments thereof for the diagnosis and/or prognosis of a neurodegenerative disease and a method for detecting isoAsp7 A? in an isolated sample.Type: ApplicationFiled: July 17, 2018Publication date: August 20, 2020Inventors: Anke PIECHOTTA, Kathrin GNOTH, Holger CYNIS, Jens-Ulrich RAHFELD, Stephan SCHILLING, Hans-Ulrich DEMUTH
-
Publication number: 20200138922Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.Type: ApplicationFiled: January 16, 2020Publication date: May 7, 2020Inventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies
-
Patent number: 10603367Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.Type: GrantFiled: January 10, 2018Date of Patent: March 31, 2020Assignee: Probiodrug AGInventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies
-
Publication number: 20180228825Abstract: The invention relates to the use of a compound of formula (I), or a composition containing the compound, as glutaminyl cyclase (QC) inhibitor and to methods of preparation.Type: ApplicationFiled: September 15, 2016Publication date: August 16, 2018Applicants: Hochschule Anhalt, Leibniz-Institut Für Pflanzenbiochemie (IPB)Inventors: Stephanie Hielscher-Michael, Carola Griehl, Hans-Ulrich Demuth, Stephan Schilling, Ludger Wessjohann, Norbert Arnold
-
Publication number: 20180140689Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.Type: ApplicationFiled: January 10, 2018Publication date: May 24, 2018Inventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Steven Gillies
-
Publication number: 20170363645Abstract: The invention relates to a highly sensitive method for the detection of pGlu-Abeta (pGlu-A?) peptides and the use of this method in the diagnosis of neurodegenerative diseases, such as Alzheimer's disease and Mild Cognitive Impairment. The invention further concerns a novel method for monitoring the effectiveness of a treatment of neurode-generative diseases by monitoring changes in the level of pGlu-A? peptides.Type: ApplicationFiled: December 18, 2015Publication date: December 21, 2017Inventors: Martin Kleinschmidt, Torsten Hoffmann, Jens-Ulrich Rahfeld, Stephan Schilling, Beena Punnamoottil, Michael Adler
-
Patent number: 9734326Abstract: A protection unit of an interrupt stack accessible by a CPU controlled by one software program, for storing and removing stack frame(s), the stack protection unit being coupleable to the stack and the CPU, comprising: a processor coupled to a first and a second address register; wherein, when a first stack frame is stored onto the stack and the execution of the software program is suspended by the CPU, responsive to one or more occurring hardware IRQs; the processing unit is adapted to set one access rule based on the first and second address registers, preventing: the occurring ISR to be serviced, from accessing a hardware-protected region of the stack, comprising at least the first stack frame and at least one stack frame associated with one or more suspended IRQs. A processor, a method and a computer program are also claimed.Type: GrantFiled: February 4, 2014Date of Patent: August 15, 2017Assignee: NXP USA, Inc.Inventors: Dirk Heisswolf, Andreas Ralph Pachl, Alexander Stephan Schilling
-
Patent number: 9676843Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.Type: GrantFiled: September 3, 2015Date of Patent: June 13, 2017Assignee: PROBIODRUG AGInventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gnoth, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
-
Patent number: 9657089Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.Type: GrantFiled: May 19, 2014Date of Patent: May 23, 2017Assignee: PROBIODRUG AGInventors: Martin Kleinschmidt, Stephan Schilling, Jens-Ulrich Rahfeld, Kristin Ebermann, Hans-Ulrich Demuth
-
Publication number: 20170097365Abstract: A method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Down's syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator. The use of antibodies binding to QC and kits for performing said diagnostic method are also provided.Type: ApplicationFiled: December 14, 2016Publication date: April 6, 2017Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Jens-Ulrich Rahfeld, Astrid Kehlen, Monique Haegele
-
Patent number: 9462793Abstract: The present invention provides a knock-out non-human animal, in particular a mouse carrying a Qpct knock-out mutation. The present invention additionally provides the respective cells and cell lines and methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.Type: GrantFiled: January 14, 2009Date of Patent: October 11, 2016Assignee: PROBIODRUG AGInventors: Stephan Schilling, Torsten Hoffmann, Hans-Ulrich Demuth
-
Patent number: 9369150Abstract: A method for protecting a data item against unauthorized access and a data processing device is disclosed comprising a memory unit and a memory control unit to protect data items stored in the memory unit against prohibited access. Upon a write access the memory control unit forms a first data word comprising a data item and a first key; computes a first error-detection code; and stores the data item along with the first error-detection code. Upon a read access the memory control unit reads the data item and the first error-detection code; forms a second data word comprising the data item and a second key; computes a second error-detection code to the second data word; and determines a syndrome on the basis of the first error-detection code and the second error-detection code, wherein the syndrome is indicative of whether or not the first and second data words are identical.Type: GrantFiled: July 29, 2014Date of Patent: June 14, 2016Assignee: FREESCALE SEMICONDUCTOR, INC.Inventors: Dirk Heisswolf, Andreas Ralph Pachl, Alexander Stephan Schilling
-
Patent number: 9277737Abstract: A knock-out non-human animal, in particular a mouse, carrying a QPCTL knock-out mutation. Additionally, respective cells and cell lines and methods and compositions for evaluating agents that affect QPCTL, for use in compositions for the treatment of QPCTL-related diseases are disclosed.Type: GrantFiled: May 6, 2013Date of Patent: March 8, 2016Assignee: PROBIODRUG AGInventors: Hans-Ulrich Demuth, Anett Stephan, Birgit Koch, Holger Cynis, Stephan Schilling, Reinhard Sedlmeier, Sigrid Graubner
-
Publication number: 20160053001Abstract: Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.Type: ApplicationFiled: September 3, 2015Publication date: February 25, 2016Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gans, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
-
Publication number: 20160036463Abstract: A method for protecting a data item against unauthorized access and a data processing device is disclosed comprising a memory unit and a memory control unit to protect data items stored in the memory unit against prohibited access. Upon a write access the memory control unit forms a first data word comprising a data item and a first key; computes a first error-detection code; and stores the data item along with the first error-detection code. Upon a read access the memory control unit reads the data item and the first error-detection code; forms a second data word comprising the data item and a second key; computes a second error-detection code to the second data word; and determines a syndrome on the basis of the first error-detection code and the second error-detection code, wherein the syndrome is indicative of whether or not the first and second data words are identical.Type: ApplicationFiled: July 29, 2014Publication date: February 4, 2016Applicant: FREESCALE SEMICONDUCTOR, INC.Inventors: DIRK HEISSWOLF, ANDREAS RALPH PACHL, ALEXANDER STEPHAN SCHILLING
-
Publication number: 20150361167Abstract: Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE).Type: ApplicationFiled: August 31, 2015Publication date: December 17, 2015Inventors: Holger Cynis, Hans-Ulrich Demuth, Jens-Ulrich Rahfeld, Stephan Schilling, Kathrin Gans, Sonja Kampfer